KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Raw Materials (2016 - 2020)

Historic Raw Materials for Emergent BioSolutions (EBS) over the last 11 years, with Q1 2020 value amounting to $77.7 million.

  • Emergent BioSolutions' Raw Materials changed N/A to $77.7 million in Q1 2020 from the same period last year, while for Mar 2020 it was $77.7 million, marking a year-over-year change of. This contributed to the annual value of $70.5 million for FY2019, which is 3610.04% up from last year.
  • According to the latest figures from Q1 2020, Emergent BioSolutions' Raw Materials is $77.7 million.
  • Emergent BioSolutions' 5-year Raw Materials high stood at $77.7 million for Q1 2020, and its period low was $25.7 million during Q1 2016.
  • Its 5-year average for Raw Materials is $43.3 million, with a median of $34.3 million in 2017.
  • Its Raw Materials has fluctuated over the past 5 years, first tumbled by 67.5% in 2018, then surged by 10387.06% in 2019.
  • Emergent BioSolutions' Raw Materials (Quarter) stood at $30.7 million in 2016, then grew by 17.64% to $36.1 million in 2017, then surged by 43.49% to $51.8 million in 2018, then skyrocketed by 36.1% to $70.5 million in 2019, then rose by 10.21% to $77.7 million in 2020.
  • Its last three reported values are $77.7 million in Q1 2020, $70.5 million for Q4 2019, and $69.0 million during Q3 2019.